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The Clinical and Angiographic analysis with a Cobalt Alloy Coronary Stent (Driver)
(CLASS) study was a prospective, nonrandomized, multicenter study designed to
assess the safety and efficacy of a cobalt-chromium alloy-based stent in patients with
stable or unstable angina pectoris. A total of 203 lesions were treated in 202 enrolled
patients. The percentage of major adverse cardiac event-free patients was 87.6% (177
of 202) at 6 months (primary safety end point; major adverse cardiac events were
defined as death, myocardial infarction, emergency bypass surgery, or target lesion
revascularization [percutaneous transluminal coronary angioplasty or coronary ar-
tery bypass grafting]). The angiographic success rate (primary efficacy end point) was
100%, and the procedural success rate was 98%. The binary in-stent restenosis rate at
6 months was 12.6%. Our results have demonstrated that the Driver cobalt-chromium
alloy stent can be used with a low 6-month incidence of major adverse cardiac events,
a low 6-month binary restenosis rate, and high angiographic and procedural success




























mhe Medtronic Driver stent (Medtronic Vascular, Santa Rosa,
alifornia) is composed of a cobalt-chromium alloy and is
imilar in design to the Medtronic S7 stent. The design is based
n elements 1.0 mm in length with an elliptical-rectangular
trut cross section and a strut thickness of 0.0036 in. (91 m).
he cobalt-chromium alloy has superior mechanical properties
ompared with traditional 316L stainless steel, including
reater strength and increased density. These properties have
llowed the development of stents with thinner struts, offering
ncreased flexibility and ease of delivery, without compromis-
ng radial strength or radiopacity. The strut thickness has been
hown to be an important determinant of the long-term reste-
osis rate.1–4 This prospective, nonrandomized, multicenter
tudy was designed to assess the safety and efficacy of the
edtronic Driver stent.
• • •
atients with clinical evidence of stable or unstable angina
ectoris, or positive functional study findings, with a
aCentre Hospitalier Universitaire Sart Tilman, Liege, Belgium; bRig-
hospitalet, Copenhagen, Denmark; cKrankenhaus der Barmherzigen
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emeen Ziekenhuis, Middelheim, Antwerp, Belgium; hSt. Charles Hospi-
al, Beirut, Lebanon; and iVrije Universiteit Medical Center, Amsterdam,
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rocedure of a single de novo lesion in a native coronary
rtery were considered for inclusion. Lesions (13 mm)
ituated in a major coronary artery or major branch with
stimated stenosis of 50% to 100% and a diameter suitable
or implantation of a single stent with a diameter of 3.0 to
.0 mm were considered eligible for enrollment.
Preprocedural antiplatelet therapy was administered ac-
ording to local routine with the following recommenda-
ions: aspirin (minimum 75 mg/day) and ticlopidine (500
g loading dose followed by 250 mg twice daily) or aspirin
nd clopidogrel (300 mg loading dose followed by 75 mg/
ay). It was initiated 24 hours before the procedure or
efore the conclusion of the catheterization. Ticlopidine or
lopidogrel were discontinued after 14 to 28 days, and
spirin (75 mg/day) was maintained indefinitely (6
onths after implantation).
After introduction of the arterial sheath (6Fr) and cath-
ter, heparin was administered. The dose was adjusted to
aintain an activated clotting time of 250 seconds (or
200 seconds if a glycoprotein IIb/IIIa platelet inhibitor
as used) throughout the procedure. A stent of sufficient
ength and diameter to cover the target lesion was selected.
tents 3.0, 3.5, and 4.0 mm in diameter and 9.0, 12.0, and
5.0 mm long were available for use. The lesion was either
retreated with standard balloon angioplasty or the direct
tenting technique was used, according to preference. Stent
eployment was assessed visually, guided by on-line quanti-
ative coronary angiographic measurement of the minimal lu-






















































































350 The American Journal of Cardiology (www.AJConline.org)An electrocardiogram was obtained within 7 days before
he procedure and between 18 and 24 hours after the pro-
edure or before discharge. Cardiac enzyme levels were
easured within 7 days before the procedure and 8 to 16
ours after the procedure. Clinical status (including anginal
tatus and adverse events) was assessed at discharge. Clin-
cal follow-up was performed at 30  5 days by telephone
r clinic visit and at 6 months (22 to 28 weeks) after the
rocedure. Anginal status was determined, and adverse
vents were documented. Angiography was performed at 6
onths on all patients who had received a Driver stent. All
ngiographic data were analyzed by the Core Laboratory
Heart Core BV, Leiden, The Netherlands).
able 1
aseline demographic and clinical characteristics (n  202)
haracteristic





oronary artery bypass grafting 2.0%
ercutaneous transluminal coronary angioplasty 12.9%
ypertension 53.0%




moker or exsmoker 70.3%
table angina pectoris 47.5%
nstable angina pectoris 40.6%
ilent myocardial ischemia 11.9%
able 2
ngiographic characteristics (n  203)
ean lesion length 11.4  4.4
efore procedure (n  203)
RVD (mm) 3.0  0.5
MLD (mm) 1.0  0.4
DS  SD 66.4  11.3%
fter procedure (n  199)
RVD (mm) 3.1  0.4
MLD (mm) 2.9  0.4
In-lesion DS  SD 11.5  10.4%
In-stent DS  SD 8.0  7.6%
ix-month (n  187)
RVD (mm) 3.0  0.5
MLD (mm) 2.1  0.6
In-lesion DS  SD 32.5  18.6%
In-stent DS  SD 29.7  16.7%
In-stent late loss (mm) 0.8  0.5
In-stent binary restenosis 12.6%




Data are presented as means  SD or percentages.
DS  diameter stenosis; RVD  reference vessel diameter; MLD 
inimal lumen diameter.The primary safety end point was the proportion of hatients without a major adverse cardiac event at 6 months.
he primary efficacy end point was the angiographic suc-
ess rate (postprocedural stenosis of 50% by core labora-
ory assessment). A major adverse cardiac event was any of
he following: death, myocardial infarction (Q-wave and
on–Q-wave), emergency bypass surgery, and target lesion
evascularization (repeat percutaneous transluminal coro-
ary angioplasty or coronary artery bypass grafting). The
econdary end points were the binary 6-month restenosis
ate (50% diameter stenosis at follow-up angiography),
rocedural success rate (proportion of patients with 50%
iameter stenosis after the procedure, as assessed by the
ore laboratory, and no major adverse cardiac event during
he hospital stay), and the proportion of patients without a
ajor adverse cardiac event at 30 days.
All data were analyzed on an intent-to-treat basis, using
escriptive statistical techniques. The difference in late loss
t the proximal and distal edges was analyzed using the
ilcoxon signed-rank test for non-normally distributed data
o establish whether it differed significantly from 0. The
ffect of the stenting method (i.e., direct stenting vs predi-
ation) on the late loss difference was assessed using a
onparametric analysis of variance test (Kruskal-Wallis
est).
Between October 2002 and May 2003, 202 patients were
nrolled at 13 centers. The baseline data are listed in Tables
and 2. One patient had 2 lesions that were treated using a
tudy stent. A total of 203 lesions in 202 patients were
herefore available for evaluation at baseline.
Three patients died before the 30-day follow-up evalua-
ion; thus, 199 patients completed the 30-day follow-up
valuation. Of the 3 deaths, 1 was considered to be the result
f in-stent thrombosis, and the other 2 were unrelated to the
tent; 1 patient with acute depression committed suicide and
he other death was due to a cardiac-related event. A total of
98 patients completed the 6-month follow-up visit, with 1
atient lost to follow-up between visits.
A total of 220 stents (217 Driver stents and 3 nonstudy
tents) were used for the 203 procedures. Direct stenting
as used in 118 of 202 patients (58.4%) and predilatation
as used in 84 (41.6%). Postprocedural angiographic data
ere available for 199 lesions in 198 patients. The angio-
raphic success rate for the lesions analyzed was 100%, and
he procedural success rate was 98% (194 of 198 patients).
he mean diameter stenosis of the target lesion was reduced
rom 66.4% before to 11.5% after the procedure.
The in-stent and in-segment binary restenosis rate
50% diameter stenosis) at 6 months was 12.6% (22 of
74 patients; Table 2). The overall mean in-stent late loss at
months was 0.83 mm, based on data from 147 lesions (92
rom the predilatation group and 55 from the direct stenting
roup). Late loss was not significantly different between
atients who underwent direct stenting or stenting after
redilatation (0.86 vs 0.77 mm, respectively, p  0.25;
igure 1). The proximal edge late loss was significantly



































































351Coronary Artery Disease/Medtronic Driver Stent: Clinical Evaluationhe entire set of patients and in the 2 subgroups defined by
irect stenting and predilatation.
The frequency of major adverse cardiac events during
he 6-month follow-up is listed in Table 3. The proportion of
atients without a major adverse cardiac event at 6 months
fter the procedure was 87.6% (177 of 202).
• • •
he present study was designed to assess the safety and
fficacy of the Medtronic Driver stent in patients with stable
nd unstable angina for the treatment of single de novo
esions in native coronary arteries. The Driver stent was
eployed with a high degree of procedural and angiographic
uccess, similar to results obtained from studies using stents
anufactured from stainless steel (87% to 100%).5–10 The
rimary safety outcome, the cumulative incidence of major
dverse cardiac events at 6 months, also compared favor-
bly with that in studies using stainless steel stents.7,8,10
urthermore, the procedural and angiographic success rates
e observed were consistent with those obtained from the
ecently completed Driver Registry, which evaluated the
river stent in patients with symptomatic ischemic heart
isease.11
The only other cobalt-chromium alloy stent to be eval-
ated in a clinical trial is the thin-strut (0.0032 in) Guidant
igure 1. Comparison of late loss (in-stent and proximal and distal edges)
or direct stenting (dark gray bars) and stenting with predilatation (light
ray bars) groups. Black bars, overall group.
able 3





eath 0 1.5% 1.5%
yocardial infarction
Q wave 0 0 0
Non-Q wave 2.5% 2.5% 3.0%




atients with major adverse cardiac event 2.5% 4.0% 12.4%
ajor adverse cardiac event-free survival 97.5% 96.0% 87.6%ision Multi-Link stent (Guidant Corporation, Indianapolis,ndiana). The results observed in the present study are
omparable to those obtained from the Guidant Vision
ulti-Link stent registry. The degree of late loss and the
requency of binary in-stent restenosis at 6 months were
imilar.12
Several comparative studies have demonstrated that
tents with thinner struts significantly reduce the incidence
f restenosis by 40% relative to thicker strut devices.1–3
he 6-month restenosis rate and the degree of late lumen
oss observed in our study compared favorably with the
esults from other studies in which thin-strut stainless steel
tents were used.6–8
The Driver stent can be used as the platform for the
rug-eluting stent, Endeavor. Biocompatibility is an impor-
ant feature in drug-eluting stents, preventing late restenosis
nd device failure. The results of the Clinical and Angio-
raphic analysis with a Cobalt Alloy Coronary Stent
CLASS) study, in terms of restenosis rates and late loss,
uggest that the biocompatibility of the Driver stent is good.
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